DS-7080a + ranibizumab

DS-7080a + ranibizumab is a combination of two biologics for ophthalmic use. **DS-7080a** is a humanized monoclonal antibody targeting roundabout guidance receptor 4 (**ROBO4**), acting as an angiogenesis inhibitor via a mechanism distinct from anti-VEGF therapies. It inhibits vascular endothelial and non-VEGF-induced migration and neovascularization. **Ranibizumab** is a recombinant, humanized monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (**VEGF-A**), preventing abnormal blood vessel growth and leakage in ocular diseases. When combined, these agents provide additive anti-angiogenic effects, likely achieved through independent and complementary inhibition of vascular pathologies relevant to neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Studies demonstrate that combination therapy may be more effective than monotherapy by leveraging both VEGF-dependent and -independent anti-angiogenic pathways. The combination is administered by intravitreal injection and is under evaluation in clinical trials for nAMD and DME[1][2][5].